| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43e3417ee1aa985c94e4ef03f6e1b888
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6af3e27cdfa41f1e655df4a7a3393477
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f81795ae1e9b7170175b5c96364f8157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1cd682066abd493933da24193f659e4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
| filingDate |
2005-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7dc184ca4a01d81d933ab38bec86c21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f65e9d8f60c4f323ab1d727aee582e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2fdd3dda8b3525220775711960103d1 |
| publicationDate |
2006-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006072093-A2 |
| titleOfInvention |
Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone |
| abstract |
A method for reducing mortality associated with GVHD by treating the patent with an oral BDP regimen that involves co-administration of: 1) a high dose of prednisone (about 1-2 mg/kg/day) for about 10 days, which is then tapered rapidly over the following 7 days to a physiological replacement dose of about 0.0625 mg/kg/day for the remainder of the treatment, and 2) about 4 - 12 mg oral BDP q.i.d. for about 50 days, where the BDP is administered in both immediate release and enteric coated preparations. Another method is for treating leukemia by performing hematopoietic cell transplantation followed by said regimen. A significant reduction in patient mortality is observed 200 days after the start of these treatments |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3177294-A4 |
| priorityDate |
2004-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |